New York, NY, May 14, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Parkinson’s Disease Therapeutics Market by Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors and Others), by Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion) and by Distribution Channel for Hospital Pharmacy, Retail Pharmacy and Online Sales: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2023”. According to the report, global parkinson’s disease therapeutics market was valued at approximately USD 2.36 billion in 2017 and is expected to generate revenue of around USD 4.31 billion by end of 2023, growing at a CAGR of around 10.6% between 2017 and 2023.
Parkinson’s disease is a progressive movement disorder caused when dopamine-producing nerve cells function irregularly. Some of the major symptoms of Parkinson’s disease include hand, arms or leg tremors, slow movement, problems associated with balancing and walking and stiff muscles. The fact that this disease is progressive in nature debilitates the patient’s condition and the later symptoms of Parkinson’s include trouble swallowing, constipation, fixed or blank expressions, dementia and speech disabilities.
Browse through 69 Tables & 25 Figures spread over 110 Pages and in-depth TOC on "Global Parkinson’s Disease Therapeutics Market: By Type, Size, Share, Trends and Industry Forecast, 2017 - 2023”.
Request Free Sample Report of Global Parkinson’s Disease Therapeutics Market Report @ https://www.zionmarketresearch.com/sample/parkinsons-disease-therapeutics-market
According to Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 8 to 10 million people are affected by the disease and every year around 70,000 Americans are diagnosed with it. High prevalence and rise in incidence rates of Parkinson’s disease in developed countries are driving the growth of the global Parkinson’s disease therapeutics market. Also, increase in awareness about Parkinson’s disease and high clinical R&D budget by the governments and non-profit organizations are projected to fuel the growth of the Parkinson’s therapeutics market during the forecast period. The promising product pipeline represents the potential business development opportunities during the forecast period.
The Parkinson’s disease therapeutics market is segmented on the basis of drug type into levodopa combination, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, anticholinergic drugs, catechol-o-methyltransferase (COMT) inhibitors and others. Levodopa combination therapy dominated the global Parkinson’s disease therapeutics market, holding a larger share since Levodopa combination therapy is considered a highly effective treatment for controlling the motor symptoms throughout the stages of Parkinson’s disease.
Download Free Report Brochure: https://www.zionmarketresearch.com/requestbrochure/parkinsons-disease-therapeutics-market
The Parkinson’s disease therapeutics market is segmented on the basis of route of administration into the oral, transdermal, subcutaneous, and intestinal infusion. The oral route of administration accounted for the leading share of the global market. Also, the recent launch of Duopa in the U.S. has contributed to a significant share of the intestinal infusion segment in the global market.
Europe accounted for the largest share of the global Parkinson’s disease therapeutics market. High level of awareness, increase in funding for research and grants, favorable medical reimbursement policies, high prevalence of Parkinson’s disease, rapidly growing geriatric population, and promising clinical pipeline products have contributed to the key share of Europe in the Parkinson’s disease therapeutics market. Europe is a highly attractive market and is expected to expand at a significant CAGR during the forecast period.
Browse the full "Parkinson’s Disease Therapeutics Market by Drug Class (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors and Others), by Route of Administration (Oral, Transdermal, Subcutaneous, and Intestinal Infusion) and by Distribution Channel for Hospital Pharmacy, Retail Pharmacy and Online Sales: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2023" report at https://www.zionmarketresearch.com/report/parkinsons-disease-therapeutics-market
North America holds a substantial market share in the global Parkinson’s disease therapeutics market. According to Parkinson’s disease Foundation (PDF), approximately 60,000 Americans have diagnosed with Parkinson’s disease annually. For instance, in the U.S. over 40 medicines are being developed for the treatment and diagnosis of Parkinson’s disease many of which have gained fast-track designation from the U.S. FDA.
The Asia-Pacific market is projected to have the highest CAGR during the forecast period. A major share of the market is captured by Japan and China in the Asia Pacific, primarily due to the large base of elderly people affected with Parkinson’s disease in these countries.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/parkinsons-disease-therapeutics-market
Latin America and the Middle East and Africa are anticipated to exhibit high growth rates. Brazil accounts for a major industry share with increasing prevalence of Parkinson’s disease fostering market growth in this region followed by other countries.
Some of the key players in Parkinson’s disease therapeutics market include Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., UCB, Inc., STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., Impax Laboratories, Inc., and Others.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/2858
This report segments the global Parkinson’s disease therapeutics market as follows:
Global Parkinson’s Disease Therapeutics Market: Drug Class Segment Analysis
- Levodopa Combination
- Dopamine Agonists
- Monoamine Oxidase B (Mao-B) Inhibitors
- Anticholinergic Drugs
- Catechol-O-Methyltransferase (Comt) Inhibitors
- Others
Global Parkinson’s Disease Therapeutics Market: Route of Administration Segment Analysis
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
Global Parkinson’s Disease Therapeutics Market: Distribution Channel Segment Analysis
- Hospital Pharmacy
- Retail Pharmacy
- Online Sales
Global Parkinson’s Disease Therapeutics Market: Regional Segment Analysis
- North America
- The U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
Related Reports:
- Geriatric Care Services Market: https://www.zionmarketresearch.com/report/geriatric-care-services-market
- Healthcare Supply Chain Management Market: https://www.zionmarketresearch.com/report/healthcare-supply-chain-management-market
- Cell Culture Media Market: https://www.zionmarketresearch.com/report/cell-culture-media-market
- Ventilator Market: https://www.zionmarketresearch.com/report/ventilator-market
- IoT Healthcare Market: https://www.zionmarketresearch.com/report/iot-healthcare-market
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
Blog: http://industrydailynews.com | http://www.e-marketresearch.com | http://marketglobalnews.com | http://theindustrytoday.com | https://detroitnews24.com | http://thebookofkindle.com